New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
07:59 EDTCLDXCelldex reiterated as a Focus Pick at Roth Capital
Roth Capital reiterated Celldex as its Focus Pick citing its broad pipeline and the potential for accelerated approval for either ORR or PFS. Shares are Buy rated with a $16 price target.
News For CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
08:57 EDTCLDXLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 13, 2015
17:28 EDTCLDXCelldex to present data from Phase 2 ReACT study of Rintega at ASCO
Celldex Therapeutics announced that several clinical programs, including the Phase 2 ReACT study of Rintega in patients with recurrent glioblastoma, or GBM, will be presented at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting in Chicago. The ReACT presentation will include final analysis of progression-free survival at 6 months, or PFS6, and current data on overall survival and other endpoints. Data contained in the published abstract were from an analysis in October 2014. Data to be presented in the oral session will include comprehensive data from the study through March.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use